AbbVie Non-GAAP EPS of $3.82 beats by $0.05, revenue of $17.4B beats by $50M, raises FY guid

AbbVie won a legal battle against the US government over Botox's inclusion in a price negotiation program. A federal judge ruled that Botox, derived from human plasma, is excluded from the program. The ruling cited an incorrect interpretation of the exclusion by the Centers for Medicare & Medicaid Services (CMS).

Pfizer's Michael Burns shared new clinical data on ABBV-400 (telisotuzumab adizutecan) in metastatic colorectal cancer. The randomized Phase 1 study, published in Annals of Oncology, evaluated the novel c-Met-directed antibody-drug conjugate combined with anti-VEGF therapy. The study explored efficacy and tolerability in heavily pretreated patients, with Phase 3 trials ongoing.

Eli Lilly (LLY) and AbbVie (ABBV) hit all-time highs after strong Q3 earnings. LLY reported 39% revenue growth, raised 2026 outlook, and saw target prices increase. ABBV revenue rose 10.3%, and it raised FY 2026 guidance. Analysts cite obesity-drug leadership and immunology growth as drivers.

AbbVie (ABBV) raised its 2026 adjusted EPS guidance to $13.95-$13.99 and increased expected revenue to $67.8B. CEO Robert Michael cited strong performance and a dividend increase. The company's Q3 2026 results exceeded expectations, according to management.

AbbVie (NYSE:ABBV) shares rose 1.75% to $295.88 on October 30 after raising its earnings outlook and dividend. Skyrizi and Rinvoq contributed 48.7% of its $17.404 billion quarterly revenue. The company increased its full-year adjusted earnings forecast to $13.95-$13.99 per share and its quarterly dividend to $1.82, starting in February 2027.

AbbVie reported Q3 earnings, with Humira sales down 30.6% to $683M due to biosimilar competition. Neuroscience revenue rose 19.5% to $3.4B, leading to an increased full-year outlook. Oncology revenue grew 0.9% to $1.7B, with VENCLEXTA sales up 10.7%. The company expects multiple pipeline advancements and maintained its aesthetics outlook at $5B.